Wednesday, April 18, 2018
The Clobazam Pathway on the Cover of Pharmacogenetics and Genomics
One of our newest pathways, the Clobazam Pathway, Pharmacokinetics, is featured on the cover of the April issue of the journal Pharmacogenetics and Genomics. PharmGKB Scientific Curator Dr. Rachel Huddart is the first author on this pathway. Clobazam is a benzodiazepine and is used primarily as an anti-epileptic. The primary metabolizing enzyme is CYP2C19, but additional metabolizing enzymes include CYP3A4, CYP2B6 and CYP2C18. You can now view the interactive Clobazam Pathway, Pharmacokinetics on PharmGKB.